BRPI0414425A - composições farmacêuticas - Google Patents

composições farmacêuticas

Info

Publication number
BRPI0414425A
BRPI0414425A BRPI0414425-2A BRPI0414425A BRPI0414425A BR PI0414425 A BRPI0414425 A BR PI0414425A BR PI0414425 A BRPI0414425 A BR PI0414425A BR PI0414425 A BRPI0414425 A BR PI0414425A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
relates
present
administration
useful
Prior art date
Application number
BRPI0414425-2A
Other languages
English (en)
Inventor
David Morton
David Ganderton
John Staniforth
Yorick Kamlag
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0321611.6A external-priority patent/GB0321611D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of BRPI0414425A publication Critical patent/BRPI0414425A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS". A presente invenção refere-se à composições farmacêuticas que são úteis no tratamento de doenças onde o excesso de muco está presente no trato respiratório, tal como fibrose cística e doença pulmonar obstrutiva crónica. Em particular, a invenção se refere à composições farmacêuticas para administração por inalação pulmonar.
BRPI0414425-2A 2003-09-15 2004-09-15 composições farmacêuticas BRPI0414425A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0321611.6A GB0321611D0 (en) 2003-09-15 2003-09-15 Pharmaceutical compositions
GBGB0327723.3A GB0327723D0 (en) 2003-09-15 2003-11-28 Pharmaceutical compositions
PCT/GB2004/003932 WO2005025540A2 (en) 2003-09-15 2004-09-15 Mucoactive agents for treating a pulmonary disease

Publications (1)

Publication Number Publication Date
BRPI0414425A true BRPI0414425A (pt) 2006-11-14

Family

ID=34315438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414425-2A BRPI0414425A (pt) 2003-09-15 2004-09-15 composições farmacêuticas

Country Status (15)

Country Link
US (2) US7928089B2 (pt)
EP (2) EP1663151A2 (pt)
JP (2) JP4913595B2 (pt)
KR (1) KR20060082865A (pt)
CN (1) CN1874757B (pt)
AU (1) AU2004271778B2 (pt)
BR (1) BRPI0414425A (pt)
CA (1) CA2538399A1 (pt)
GB (1) GB0327723D0 (pt)
IL (1) IL173987A0 (pt)
NO (1) NO20061254L (pt)
NZ (1) NZ545550A (pt)
RU (1) RU2363448C2 (pt)
SG (1) SG146649A1 (pt)
WO (1) WO2005025540A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
HUE056086T2 (hu) 2006-03-15 2022-01-28 Brigham & Womens Hospital Inc Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
MX2009003002A (es) * 2006-09-19 2009-06-01 Discovery Lab Inc Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
CN101433521B (zh) * 2007-11-14 2012-08-08 中国医学科学院药用植物研究所 药用可吸入微粒、使用其的肺部吸入制剂及其制备方法
HUE032875T2 (en) 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
US8685458B2 (en) 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP3130396B1 (en) 2009-03-27 2021-03-17 Bend Research, Inc. Spray-drying process
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012073025A1 (en) * 2010-11-30 2012-06-07 Vectura Limited Glucosaminoglucans such as heparin for use in the treatment of pulmonary inflammation such as copd
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
WO2013119705A2 (en) * 2012-02-06 2013-08-15 University Of Iowa Research Foundation Method of regulating cftr expression and processing
US9707228B2 (en) * 2012-05-21 2017-07-18 Agency For Science, Technology And Research Dry powder formulation
ITMI20121052A1 (it) * 2012-06-18 2013-12-19 Ecupharma Srl Formulazioni inalatorie per la rimozione delle secrezioni viscose dall'apparato respiratorio
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9078853B2 (en) * 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
JP6502501B2 (ja) 2014-09-09 2019-04-17 ベクトゥラ・リミテッド グリコピロレートを含む製剤、方法、及び装置
SG11201702614SA (en) * 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
KR102364212B1 (ko) * 2014-10-10 2022-02-17 아블린쓰 엔.브이. 호흡기 질병들의 에어로졸 치료에 사용하기 위한 흡입 디바이스
JP2017538779A (ja) 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
PT3212169T (pt) 2014-10-31 2021-05-06 Bend Res Inc Processo para formar domínios ativos dispersos numa matriz
CN105920020B (zh) * 2016-06-23 2019-01-08 潘海英 一种治疗肺部疾病的药物组合物及其制备方法和用途
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
CA3039485A1 (en) * 2016-10-14 2018-04-19 Pulmatrix Operating Company, Inc. Antifungal dry powders
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
TR201722950A2 (tr) * 2017-12-29 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Koah tedavisinde yeni farmasötik bileşimler.
IT201800007928A1 (it) * 2018-08-07 2020-02-07 Sofar Spa Composizione contenente un agente mucolitico per il trattamento di ipersecrezione di muco e dispositivo per il suo dosaggio
WO2020191076A1 (en) * 2019-03-18 2020-09-24 Cedars-Sinai Medical Center Compositions and methods to treat gastrointestinal diseases and disorders
JOP20210305A1 (ar) 2019-05-16 2023-01-30 Aerovate Therapeutics Inc صيغ إيماتينيب وتصنيعها واستخداماتها
KR102250876B1 (ko) * 2019-07-18 2021-05-11 충북대학교 산학협력단 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734401A (en) 1986-03-17 1988-03-29 W. R. Grace & Co. Process for spray drying amino acid compositions
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
WO1993017663A1 (en) 1992-03-10 1993-09-16 Fisons Plc Pharmaceutical inhalation compositions
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
ES2295087T3 (es) * 1992-07-24 2008-04-16 Thomas P. Kennedy Heparinas desulfatadas no anticoagulantes como medicamentos.
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
DE69637441T2 (de) 1995-10-17 2009-03-05 Jagotec Ag Verabreichung unlöslicher arzneistoffe
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
ATE247948T1 (de) 1996-04-29 2003-09-15 Dura Pharma Inc Verfahren zum inhalieren trockener pulver
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
AU727352B2 (en) * 1996-07-29 2000-12-14 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
WO1998029098A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6075013A (en) 1997-06-06 2000-06-13 Hamilton Civic Hospitals Research Development Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US20010046974A1 (en) 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CA2209342A1 (en) 1997-06-30 1998-12-30 The University Of British Columbia Use of dextran and other oligomeric saccharides to improve airway clearance
IT1296998B1 (it) 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
US20030118514A1 (en) 1998-03-26 2003-06-26 Glaxo Wellcome Inc. Compositions for inhalation
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
IT1309592B1 (it) 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
US6440463B1 (en) 1999-04-05 2002-08-27 Pharmaceutical Discovery Corporation Methods for fine powder formation
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6560897B2 (en) 1999-05-03 2003-05-13 Acusphere, Inc. Spray drying apparatus and methods of use
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
HUP0201712A3 (en) 1999-06-30 2003-03-28 Weitz Jeffrey I Ancaster Clot associated coagulation factors inhibiting heparin compositions
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ES2161615B1 (es) 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US20020081266A1 (en) 1999-08-20 2002-06-27 Norton Healthcare Ltd. Spray dried powders for pulmonary or nasal administration
EP1212047A2 (en) * 1999-08-26 2002-06-12 The Governors Of The University Of Alberta Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
MXPA02004193A (es) 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
DE19953317C1 (de) * 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
CA2340836A1 (en) 2000-03-18 2001-09-18 Degussa Ag Granular product
US6369115B1 (en) 2000-03-20 2002-04-09 Dura Pharmaceuticals, Inc. Stabilized powder formulations
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
US20050032745A1 (en) 2000-05-04 2005-02-10 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
CN1197587C (zh) 2000-06-09 2005-04-20 中国科学院上海细胞生物学研究所 N－位脱硫酸肝素在预防和治疗炎症中的应用
WO2002000197A1 (en) 2000-06-27 2002-01-03 Vectura Limited Method of making particles for use in a pharmaceutical composition
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6969705B2 (en) 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物
ATE420630T1 (de) 2000-11-29 2009-01-15 Itoham Foods Inc Pulverzubereitungen und verfahren zu ihrer herstellung
ES2296831T3 (es) 2000-11-30 2008-05-01 Vectura Limited Metodo para preparar microparticulas para usar en composiciones farmaceuticas para inhalacion.
PT1920763E (pt) 2000-11-30 2014-06-25 Vectura Ltd Composições farmacêuticas para inalação
EP1337239B2 (en) 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
US6994842B2 (en) 2000-12-22 2006-02-07 Aspen Aerogels, Inc. Aerogel powder therapeutic agents
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
GB0106403D0 (en) 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US20030091513A1 (en) 2001-10-03 2003-05-15 Mohsen Nahed M. Method to generate water soluble or nonwater soluble in nanoparticulates directly in suspension or dispersion media
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20050013867A1 (en) 2001-10-19 2005-01-20 Lehrman S. Russ Use of proton sequestering agents in drug formulations
DE60227691D1 (de) 2001-11-01 2008-08-28 Nektar Therapeutics Sprühtrocknungsverfahren
AU2002366267B2 (en) 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US20060188451A1 (en) 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
US20030124087A1 (en) * 2001-12-26 2003-07-03 Amitie Co. Ltd. Anti-adhesion barrier
DK1549337T3 (en) * 2002-02-18 2014-11-24 Ockham Biotech Ltd COMBINATION OF DNASE I AND GLYCOSAMINOGLYCANES FOR USE IN EXTRACELLULAR DNA CLEARANCE
ES2565028T3 (es) * 2002-02-18 2016-03-30 Ockham Biotech Limited Terapia de combinación para trastornos respiratorios
DE60323973D1 (de) * 2002-02-18 2008-11-20 Univ Southampton Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
US20030232019A1 (en) * 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
FI116657B (fi) 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
EP1494652A1 (en) 2002-04-12 2005-01-12 Campina Nederland Holding B.V. Excipient for use in dry powder inhalation preparations
WO2003092654A1 (en) 2002-05-02 2003-11-13 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US20040028746A1 (en) 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20040043064A1 (en) 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission
JP2006503865A (ja) 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
GB0304540D0 (en) 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
US6933372B2 (en) 2003-03-07 2005-08-23 Warner-Lambert Company Method to produce a solid form of heparin
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
CA2435632A1 (en) 2003-07-21 2005-01-21 Warren Hugh Finlay Formulation of powder containing nanoparticles for aerosol delivery to the lung
AU2004258971A1 (en) 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
ATE498394T1 (de) 2003-09-02 2011-03-15 Norton Healthcare Ltd Verfahren zur herstellung eines medikaments
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004278013B2 (en) 2003-10-01 2009-01-15 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
NZ546379A (en) 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
CN1261105C (zh) 2003-12-05 2006-06-28 吉林省辽源亚东药业股份有限公司 一种复方吡拉西坦脑蛋白水解物制剂及制备方法
GB0329208D0 (en) 2003-12-17 2004-01-21 Ici Plc Particulate materials
EP1697034A1 (en) 2003-12-23 2006-09-06 Niro A/S A METHOD AND APPARATUS FOR PRODUCING MICRO PARTICLES sp /sp
US7928059B2 (en) * 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
EP1748781B1 (en) 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
WO2006033693A2 (en) 2004-06-30 2006-03-30 Deangelis Paul L Methods of selectively treating diseases with specific glycosaminoglycan polymers
WO2006019894A2 (en) 2004-07-14 2006-02-23 O'connor Michael F Nebulized pharmaceutical compositions for the treatment of bronchial disorders
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1845946A2 (en) 2005-02-10 2007-10-24 Orexo AB Pharmaceutical compositions useful in the transmucosal administration of drugs
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US20090186088A1 (en) 2005-03-18 2009-07-23 Nanomaterials Technology Pte Ltd Inhalable drug
KR20140002810A (ko) 2005-05-05 2014-01-08 사노피-아벤티스 유.에스. 엘엘씨 안정한 나노입자 제형
CN103120701B (zh) 2005-10-12 2014-11-05 生化学工业株式会社 包含疏水基团结合型糖胺聚糖在制备预防或治疗角膜上皮层病症的药物中的用途
US20070098803A1 (en) 2005-10-27 2007-05-03 Primet Precision Materials, Inc. Small particle compositions and associated methods
US7597094B2 (en) * 2005-11-29 2009-10-06 Leon Monroe Pittman Compound bow maintenance press and method for compressing a compound bow from the bow limb ends
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CA2633254A1 (en) 2005-12-16 2007-07-05 Tap Pharmaceutical Products, Inc. Pharmaceutical compositions of ilaprazole
DE102005062270A1 (de) 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
US20070166386A1 (en) 2006-01-13 2007-07-19 Chinea Vanessa I Nanoparticle formation of pharmaceutical ingredients
US20080057129A1 (en) 2006-04-03 2008-03-06 Lerner E I Drug microparticles
US8257685B2 (en) 2006-04-04 2012-09-04 Stc.Unm Swellable particles for drug delivery
US20080299210A1 (en) 2006-04-13 2008-12-04 Min Wei Stable nanosized amorphous drug
US20080181958A1 (en) 2006-06-19 2008-07-31 Rothrock Ginger D Nanoparticle fabrication methods, systems, and materials
WO2008002485A2 (en) 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
GB0617171D0 (en) 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
US20090203789A1 (en) 2008-01-31 2009-08-13 Multi Formulations Ltd. Fast Dissolution Amino Acid Composition

Also Published As

Publication number Publication date
CN1874757B (zh) 2011-03-09
NO20061254L (no) 2006-04-11
NZ545550A (en) 2009-03-31
JP2007505830A (ja) 2007-03-15
RU2006112583A (ru) 2007-11-10
CN1874757A (zh) 2006-12-06
GB0327723D0 (en) 2003-12-31
JP4913595B2 (ja) 2012-04-11
US20110217339A1 (en) 2011-09-08
CA2538399A1 (en) 2005-03-24
EP1663151A2 (en) 2006-06-07
RU2363448C2 (ru) 2009-08-10
WO2005025540A2 (en) 2005-03-24
EP2277505A2 (en) 2011-01-26
WO2005025540A3 (en) 2005-06-16
AU2004271778A1 (en) 2005-03-24
KR20060082865A (ko) 2006-07-19
JP2012031204A (ja) 2012-02-16
AU2004271778B2 (en) 2011-04-21
EP2277505A3 (en) 2011-06-15
SG146649A1 (en) 2008-10-30
US7928089B2 (en) 2011-04-19
IL173987A0 (en) 2006-07-05
US20070065373A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
BRPI0414425A (pt) composições farmacêuticas
WO2004045618A3 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
CY1118517T1 (el) Πνευμονικη χορηγηση για λεβοντοπα
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
WO2008052044A3 (en) Use of derivatives of propofol for treating diseases associated with oxidative stress
NO20024708L (no) Behandling av respiratoriske sykdommer
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
MX2009006695A (es) P-mentan-3-carboxamida sustituida con nitrogeno y sus usos.
ATE381535T1 (de) Phenethanolaminderivate
BRPI0414428A (pt) composições farmacêuticas
CY1108900T1 (el) Πολυθειωμενα γλυκοζιδια και αλατα αυτων
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
ECSP066544A (es) Nuevas sales de tiotropio, procedimientos para su preparación, así como formulaciones medicamentosas que las contienen
WO2007057221A3 (en) Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases
BR0211450A (pt) Método terapêutico
NO20054180D0 (no) Behandling av bakterielle sykdommer i andedrettsorganene ved lokal tilforsel av fluorkinoloner
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
UY28590A1 (es) Procedimiento para la preparación de nuevas sales de tiotropio, nuevas sales de tiotropio como tales, así como las formulaciones medicamentosas que las contienen.
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
NZ597657A (en) Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2271 DE 15/07/2014.